Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Italy audit court rejects public funding for ReiThera COVID-19 vaccine-sources

05/14/2021 | 08:08am EDT

* Court blocks public investment in local biotech firm

* Italy's plan to produce own COVID vaccine at risk

* Government to decide next step in coming weeks - source

ROME, May 14 (Reuters) - Italy's hopes of producing its own COVID-19 vaccine have been thrown into doubt after the state audit court rejected a plan to pump public funds into local biotech company ReiThera, two sources close to the matter told Reuters on Friday.

A source at the audit court said it had ruled this week against a contract drawn up by state agency Invitalia to invest some 50 million euros ($60.62 million) as part of a deal with ReiThera to support its development of the new vaccine.

"The investment scheme is illegitimate, and therefore void," the source said, without providing any details.

The court normally adjudicates on whether state agencies have followed correct procedures and not on the merits of a project.

The company's vaccine has concluded stage-2 trials and the firm is in early talks with Brussels to supply the European Union. However, it needs public funding to start stage-3 trials.

Invitalia didn't immediately reply to a Reuters request for comment. The state audit court declined to comment on the case.


Stefano Colloca, a senior director at ReiThera, said he had not heard from the court.

"We're waiting to hear the official news, to find out if it's true and why this decision was made, which, as far as we know, would be unprecedented," he told Reuters.

A source from the industry ministry, which had signed the investment contract along with Invitalia and ReiThera, confirmed the audit court ruling and said a decision on what to do would be made in the coming weeks.

Prime Minister Mario Draghi's government, which inherited the project from the previous administration led by Giuseppe Conte, could either decide to re-write the contract in an effort to overcome the court objections or else drop the plan.

Alternatively, it could plow ahead regardless, but such a move in defiance of the court would be highly unusual.

ReiThera - whose aim is to produce some 100 million shots of a single-dose vaccine at a production site close to Rome this year - has been developing the project in partnership with Germany's Leukocare and Belgium's Univercells.

After encouraging results from phase 1 trials, the previous government decided to invest in the company to give Italy some independence in vaccine procurement, which at the moment relies entirely on a joint EU initiative.

The ReiThera vaccine is based on a so-called non-replicating adenoviral vector, the same technology that AstraZeneca and Johnson & Johnson have used in their shots.

Vaccinations for both those brands are recommended only for people aged 60 and above in Italy, after it and other European countries briefly halted AstraZeneca inoculations in March due to very rare cases of blood clots.

J&J supplies were also temporarily frozen due to similar concerns.

($1 = 0.8249 euros) (Additional reporting by Emilio Parodi; Writing by Angelo Amante; Editing by Crispian Balmer and Gareth Jones)

© Reuters 2021
All news about ASTRAZENECA PLC
05:07pOntarians cancelling AZ doses after new guidance, province still offering dos..
05:04pHealth Care Down Amid Defensive Bias -- Health Care Roundup
12:12pEurostoxx 50 : European shares deepen losses after hawkish Fed comments
11:25aTHE LATEST : Brazil to hit 500K deaths, 2nd highest globally
11:18aASTRAZENECA  : Ordered by Brussels Court to Deliver 80.2 Million COVID-19 Jabs t..
10:40aASTRAZENECA  : claims victory over EU in vaccine deliveries case
10:30aASTRAZENECA  : EU both claim a win in vaccine delivery tussle
09:50aASTRAZENECA  : Welcomes Belgian Court Ruling on COVID-19 Vaccine Supply to EU
09:31aASTRAZENECA  : Court orders AstraZeneca to deliver 50 million doses to EU by Sep..
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,8x
Yield 2021 2,44%
Capitalization 153 B 152 B -
EV / Sales 2021 5,30x
EV / Sales 2022 4,57x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,03 $
Last Close Price 116,84 $
Spread / Highest target 46,3%
Spread / Average Target 13,9%
Spread / Lowest Target -17,6%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.46%153 347
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939